Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues

References

• Wang W, Li A, Zhang Z, Chu C. Posttranslational modifications: regulation of nitrogen utilization and signaling. Plant Cell Physiol. 2021;62(4):543–552.
   PubMed Web of Science ®Google Scholar
• Weigle AT, Feng J, Shukla D. Thirty years of molecular dynamics simulations on posttranslational modifications of proteins. Phys Chem Chem Phys. 2022;24(43):26371–26397.
   PubMed Web of Science ®Google Scholar
• Li Z, Li S, Luo M, Jhong JH, Li W, Yao L, Pang Y, Wang Z, Wang R, Ma R, et al. DbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022;50(D1):D471–D479.
   PubMed Web of Science ®Google Scholar
• Meng F, Liang Z, Zhao K, Luo C. Drug design targeting active posttranslational modification protein isoforms. Med Res Rev. 2021;41(3):1701–1750.
   PubMed Web of Science ®Google Scholar
• Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001;98(15):8554–8559.
   PubMed Web of Science ®Google Scholar
• Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Sig Transduct Target Ther. 2020;5(1):11. Springer Nature December 1,
   PubMed Web of Science ®Google Scholar
• Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, Varshavsky A. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science. 1989;243(4898):1576–1583.
   PubMed Web of Science ®Google Scholar
• Fischer ES, Böhm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM, et al. Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512(7512):49–53.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326–2335.
   PubMed Web of Science ®Google Scholar
• Wertz IE, Wang X. From discovery to bedside: targeting the ubiquitin system. Cell Chem Biol. 2019;26(2):156–177.
   PubMed Web of Science ®Google Scholar
• He M, Cao C, Ni Z, Liu Y, Song P, Hao S, He Y, Sun X, Rao Y. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther. 2022;7(1):181.
   PubMed Web of Science ®Google Scholar
• Hines J, Gough JD, Corson TW, Crews CM. posttranslational protein knockdown coupled to receptor tyrosine kinase activation with PhosphoPROTACs. Proc Natl Acad Sci U S A. 2013;110(22):8942–8947.
   PubMed Web of Science ®Google Scholar
• Bassi ZI, Fillmore MC, Miah AH, Chapman TD, Maller C, Roberts EJ, Davis LC, Lewis DE, Galwey NW, Waddington KE, et al. Modulating PCAF/GCN5 immune cell function through a PROTAC approach. ACS Chem Biol. 2018;13(10):2862–2867.
   PubMed Web of Science ®Google Scholar
• Schiedel M, Herp D, Hammelmann S, Swyter S, Lehotzky A, Robaa D, Oláh J, Ovádi J, Sippl W, Jung M. Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). J Med Chem. 2018;61(2):482–491.
   PubMed Web of Science ®Google Scholar
• Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, Tang W. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg Med Chem Lett. 2018;28(14):2493–2497.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Lan T, Su S, Rao Y. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem Commun. 2019;55(3):369–372.
   PubMed Web of Science ®Google Scholar
• Shen Y, Gao G, Yu X, Kim H, Wang L, Xie L, Schwarz M, Chen X, Guccione E, Liu J, et al. Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders. J Med Chem. 2020;63(17):9977–9989.
   PubMed Web of Science ®Google Scholar
• Liu Z, Hu X, Wang Q, Wu X, Zhang Q, Wei W, Su X, He H, Zhou S, Hu R, et al. Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2. J Med Chem. 2021;64(5):2829–2848.
   PubMed Web of Science ®Google Scholar
• Maniaci C, Hughes SJ, Testa A, Chen W, Lamont DJ, Rocha S, Alessi DR, Romeo R, Ciulli A. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. Nat Commun. 2017;8(1):830.
   PubMedGoogle Scholar
• Li P, Ge J, Li H. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. Nat Rev Cardiol. 2020;17(2):96–115.
   PubMed Web of Science ®Google Scholar
• Fischer F, Alves Avelar LA, Murray L, Kurz T. Designing HDAC-PROTACs: lessons learned so far. Future Med Chem. 2022;14(3):143–166.
   PubMed Web of Science ®Google Scholar
• Hai Y, Christianson DW. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nat Chem Biol. 2016;12(9):741–747.
   PubMed Web of Science ®Google Scholar
• Itoh Y. Drug discovery researches on modulators of lysine-modifying enzymes based on strategic chemistry approaches. Chem Pharm Bull. 2020; 68 (1):34–45.
   PubMed Web of Science ®Google Scholar
• Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233–241.
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, Lee K-H, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, et al. FK228 (Depsipeptide) as a natural prodrug that inhibits class i histone deacetylases. Cancer Res. 2002;62(17):4916–4921.
   PubMed Web of Science ®Google Scholar
• Ning Z-Q, Li Z-B, Newman MJ, Shan S, Wang X-H, Pan D-S, Zhang J, Dong M, Du X, Lu X-P. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901–909.
   PubMed Web of Science ®Google Scholar
• Lee JH, Choy ML, Marks PA. Mechanisms of resistance to histone deacetylase inhibitors. Adv Cancer Res. 2012;116:39–86.
   PubMed Web of Science ®Google Scholar
• Cao F, de Weerd S, Chen D, Zwinderman MRH, van der Wouden PE, Dekker FJ. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). Eur J Med Chem. 2020;208:112800.
   PubMed Web of Science ®Google Scholar
• Yang K, Zhao Y, Nie X, Wu H, Wang B, Almodovar-Rivera CM, Xie H, Tang W. A cell-based target engagement assay for the identification of cereblon E3 ubiquitin ligase ligands and their application in HDAC6 degraders. Cell Chem Biol. 2020;27(7):866.e8–876.e8.
   Web of Science ®Google Scholar
• Xiong Y, Donovan KA, Eleuteri NA, Kirmani N, Yue H, Razov A, Krupnick NM, Nowak RP, Fischer ES. Chemo-proteomics exploration of HDAC degradability by small molecule degraders. Cell Chem Biol. 2021;28(10):1514.e4–1527.e4.
   Web of Science ®Google Scholar
• Keuler T, König B, Bückreiß N, Kraft FB, König P, Schäker-Hübner L, Steinebach C, Bendas G, Gütschow M, Hansen FK. Development of the first non-hydroxamate selective HDAC6 degraders. Chem Commun. 2022;58(79):11087–11090.
   PubMedGoogle Scholar
• Sinatra L, Yang J, Schliehe-Diecks J, Dienstbier N, Vogt M, Gebing P, Bachmann LM, Sönnichsen M, Lenz T, Stühler K, et al. Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity. J Med Chem. 2022;65(24):16860–16878.
   PubMed Web of Science ®Google Scholar
• Vannam R, Sayilgan J, Ojeda S, Karakyriakou B, Hu E, Kreuzer J, Morris R, Herrera Lopez XI, Rai S, Haas W, et al. Targeted degradation of the enhancer lysine acetyltransferases CBP and P300. Cell Chem Biol. 2021;28(4):503.e12–514.e12.
   Web of Science ®Google Scholar
• Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, et al. EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discov. 2022;12(3):730–751.
   PubMed Web of Science ®Google Scholar
• Brownsey DK, Rowley BC, Gorobets E, Mihara K, Maity R, Papatzimas JW, Gelfand BS, Hollenberg MD, Bahlis NJ, Derksen DJ. Identification of ligand linkage vectors for the development of P300/CBP degraders. RSC Med Chem. 2022;13(6):726–730.
   PubMedGoogle Scholar
• Ali I, Conrad RJ, Verdin E, Ott M. Lysine acetylation goes global: from epigenetics to metabolism and therapeutics. Chem Rev. 2018;118(3):1216–1252.
   PubMed Web of Science ®Google Scholar
• Hong JY, Jing H, Price IR, Cao J, Bai JJ, Lin H. Simultaneous inhibition of SIRT2 deacetylase and defatty-acylase activities via a PROTAC strategy. ACS Med Chem Lett. 2020;11(11):2305–2311.
   PubMed Web of Science ®Google Scholar
• Sharma C, Donu D, Curry AM, Barton E, Cen Y. Multifunctional activity-based chemical probes for sirtuins. RSC Adv. 2023;13(17):11771–11781.
   PubMed Web of Science ®Google Scholar
• Smalley JP, Adams GE, Millard CJ, Song Y, Norris JKS, Schwabe JWR, Cowley SM, Hodgkinson JT. PROTAC-mediated degradation of class i histone deacetylase enzymes in corepressor complexes. Chem Commun. 2020;56(32):4476–4479.
   PubMed Web of Science ®Google Scholar
• Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT. Optimization of class I histone deacetylase PROTACs reveals that HDAC1/2 degradation is critical to induce apoptosis and cell arrest in cancer cells. J Med Chem. 2022;65(7):5642–5659.
   PubMed Web of Science ®Google Scholar
• Baker IM, Smalley JP, Sabat KA, Hodgkinson JT, Cowley SM. Comprehensive transcriptomic analysis of novel class I HDAC proteolysis targeting chimeras (PROTACs). Biochemistry. 2023;62(3):645–656.
   PubMed Web of Science ®Google Scholar
• Cross JM, Coulson ME, Smalley JP, Pytel WA, Ismail O, Trory JS, Cowley SM, Hodgkinson JT. A ‘click’ chemistry approach to novel entinostat (MS-275) based class i histone deacetylase proteolysis targeting chimeras. RSC Med Chem. 2022;13(12):1634–1639.
   PubMedGoogle Scholar
• Roatsch M, Vogelmann A, Herp D, Jung M, Olsen CA. Proteolysis-targeting chimeras (PROTACs): Based on macrocyclic tetrapeptides selectively degrade class I histone deacetylases. chemrxiv. 2020:1–3.
   Google Scholar
• Xiao Y, Wang J, Zhao LY, Chen X, Zheng G, Zhang X, Liao D. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. Chem Commun. 2020;56(68):9866–9869.
   PubMed Web of Science ®Google Scholar
• Macabuag N, Esmieu W, Breccia P, Jarvis R, Blackaby W, Lazari O, Urbonas L, Eznarriaga M, Williams R, Strijbosch A, et al. Developing HDAC4-selective protein degraders to investigate the role of HDAC4 in Huntington’s disease pathology. J Med Chem. 2022;65(18):12445–12459.
   PubMed Web of Science ®Google Scholar
• An Z, Lv W, Su S, Wu W, Rao Y. Developing potent PROTACs tools for selective degradation of HDAC6 protein. Protein Cell. 2019;10(8):606–609.
   PubMed Web of Science ®Google Scholar
• Yang H, Lv W, He M, Deng H, Li H, Wu W, Rao Y. Plasticity in designing PROTACs for selective and potent degradation of HDAC6. Chem Commun. 2019;55(98):14848–14851.
   PubMed Web of Science ®Google Scholar
• Wu H, Yang K, Zhang Z, Leisten ED, Li Z, Xie H, Liu J, Smith KA, Novakova Z, Barinka C, et al. Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity. J Med Chem. 2019;62(15):7042–7057.
   PubMed Web of Science ®Google Scholar
• Yang K, Wu H, Zhang Z, Leisten ED, Nie X, Liu B, Wen Z, Zhang J, Cunningham MD, Tang W. Development of selective histone deacetylase 6 (HDAC6) degraders recruiting von Hippel-Lindau (VHL) E3 ubiquitin ligase. ACS Med Chem Lett. 2020;11(4):575–581.
   PubMed Web of Science ®Google Scholar
• Sinatra L, Bandolik JJ, Roatsch M, Sönnichsen M, Schoeder CT, Hamacher A, Schöler A, Borkhardt A, Meiler J, Bhatia S, et al. Hydroxamic acids immobilized on resins (HAIRs): synthesis of dual-targeting HDAC inhibitors and HDAC degraders (PROTACs). Angew Chem Int Ed Engl. 2020;59(50):22494–22499.
   PubMed Web of Science ®Google Scholar
• Cao Z, Gu Z, Lin S, Chen D, Wang J, Zhao Y, Li Y, Liu T, Li Y, Wang Y, et al. Attenuation of NLRP3 inflammasome activation by indirubin-derived PROTAC targeting HDAC6. ACS Chem Biol. 2021;16(12):2746–2751.
   PubMed Web of Science ®Google Scholar
• Darwish S, Heimburg T, Ridinger J, Herp D, Schmidt M, Romier C, Jung M, Oehme I, Sippl W. Synthesis, biochemical, and cellular evaluation of HDAC6 targeting proteolysis targeting chimeras. Methods Mol Biol. 2023;2589:179–193.
   PubMedGoogle Scholar
• Chotitumnavee J, Yamashita Y, Takahashi Y, Takada Y, Iida T, Oba M, Itoh Y, Suzuki T. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC). Chem Commun. 2022;58(29):4635–4638.
   PubMed Web of Science ®Google Scholar
• Sun Z, Deng B, Yang Z, Mai R, Huang J, Ma Z, Chen T, Chen J. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8. Eur J Med Chem. 2022;239:114544.
   PubMed Web of Science ®Google Scholar
• Darwish S, Ghazy E, Heimburg T, Herp D, Zeyen P, Salem-Altintas R, Ridinger J, Robaa D, Schmidtkunz K, Erdmann F, et al. Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity. Int J Mol Sci. 2022; 23 (14):7535.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang J, Xu W, Wu Q, Zeng R, Liu Z, Tao W, Chen Q, Wang Y, Zhu WG. Structure-based discovery of selective histone deacetylase 8 degraders with potent anticancer activity. J Med Chem. 2023;66(2):1186–1209.
   PubMed Web of Science ®Google Scholar
• Zhao C, Chen D, Suo F, Setroikromo R, Quax WJ, Dekker FJ. Discovery of highly potent HDAC8 PROTACs with anti-tumor activity. Bioorg Chem. 2023;136:106546.
   PubMed Web of Science ®Google Scholar
• Ali A, Zhang F, Maguire A, Byrne T, Weiner-Gorzel K, Bridgett S, O'Toole S, O'Leary J, Beggan C, Fitzpatrick P, et al. Hdac6 degradation inhibits the growth of high-grade serous ovarian cancer cells. Cancers. 2020;12(12):3734.
   PubMed Web of Science ®Google Scholar
• Shen S, Benoy V, Bergman JA, Kalin JH, Frojuello M, Vistoli G, Haeck W, Van Den Bosch L, Kozikowski AP. Bicyclic-capped histone deacetylase 6 inhibitors with improved activity in a model of axonal charcot-marie-tooth disease. ACS Chem Neurosci. 2016;7(2):240–258.
   PubMed Web of Science ®Google Scholar
• Cao J, Zhao W, Zhao C, Liu Q, Li S, Zhang G, Chou CJ, Zhang Y. Development of a bestatin-SAHA hybrid with dual inhibitory activity against APN and HDAC. Molecules. 2020;25(21):4991.
   PubMed Web of Science ®Google Scholar
• Barghout SH, Machado RAC, Barsyte-Lovejoy D. Chemical biology and pharmacology of histone lysine methylation inhibitors. Biochim Biophys Acta Gene Regul Mech. 2022;1865(6):194840.
   PubMed Web of Science ®Google Scholar
• Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26(10):880–889.
   PubMed Web of Science ®Google Scholar
• Xu J, Richard S. Cellular pathways influenced by protein arginine methylation: implications for cancer. Mol Cell. 2021;81(21):4357–4368.
   PubMed Web of Science ®Google Scholar
• Jakobsson ME, Małecki JM, Halabelian L, Nilges BS, Pinto R, Kudithipudi S, Munk S, Davydova E, Zuhairi FR, Arrowsmith CH, et al. The dual methyltransferase METTL13 targets N terminus and Lys55 of EEF1A and modulates codon-specific translation rates. Nat Commun. 2018;9(1):3411.
   PubMedGoogle Scholar
• Straining R, Eighmy W. Tazemetostat: EZH2 inhibitor. J Adv Pract Oncol. 2022;13(2):158–163.
   PubMedGoogle Scholar
• Hoy SM. Tazemetostat: first approval. Drugs. 2020;80(5):513–521.
   PubMed Web of Science ®Google Scholar
• Bisserier M, Wajapeyee N. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood. 2018;131(19):2125–2137.
   PubMed Web of Science ®Google Scholar
• Kouznetsova VL, Tchekanov A, Li X, Yan X, Tsigelny IF. Polycomb repressive 2 complex-molecular mechanisms of function. Protein Sci. 2019;28(8):1387–1399.
   PubMed Web of Science ®Google Scholar
• Crew AP, Berlin M, Dong H, Qian Y. WO2017011590A1 – alanine-based modulators of proteolysis and associated methods of use – Google Patents; 2017 [accessed 2023 May 03]. https://patents.google.com/patent/WO2017011590A1/en.
   Google Scholar
• Crew AP, Snyder LB, Wang J, Dong H, Qian Y, Berlin M. WO2018119357 compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide; 2018 [accessed 2023 May 03]. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018119357.
   Google Scholar
• Tu Y, Sun Y, Qiao S, Luo Y, Liu P, Jiang ZX, Hu Y, Wang Z, Huang P, Wen S. Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma. J Med Chem. 2021;64(14):10167–10184.
   PubMed Web of Science ®Google Scholar
• Wang J, Yu X, Gong W, Liu X, Park KS, Ma A, Tsai YH, Shen Y, Onikubo T, Pi WC, et al. EZH2 noncanonically binds CMyc and P300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat Cell Biol. 2022;24(3):384–399.
   PubMed Web of Science ®Google Scholar
• Wang C, Chen X, Liu X, Lu D, Li S, Qu L, Yin F, Luo H, Zhang Y, Luo Z, et al. Discovery of precision targeting EZH2 degraders for triple-negative breast cancer. Eur J Med Chem. 2022;238:114462.
   PubMed Web of Science ®Google Scholar
• Dale B, Anderson C, Park KS, Kaniskan HÜ, Ma A, Shen Y, Zhang C, Xie L, Chen X, Yu X, et al. Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2. ACS Pharmacol Transl Sci. 2022;5(7):491–507.
   PubMedGoogle Scholar
• Hsu JH-R, Rasmusson T, Robinson J, Pachl F, Read J, Kawatkar S, O' Donovan DH, Bagal S, Code E, Rawlins P, et al. EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex. Cell Chem Biol. 2020;27(1):41.e17–46.e17.
   Web of Science ®Google Scholar
• Potjewyd F, Turner AMW, Beri J, Rectenwald JM, Norris-Drouin JL, Cholensky SH, Margolis DM, Pearce KH, Herring LE, James LI. Degradation of polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader. Cell Chem Biol. 2020;27(1):47.e15–56.e15.
   Web of Science ®Google Scholar
• Bashore FM, Foley CA, Ong HW, Rectenwald JM, Hanley RP, Norris-Drouin JL, Cholensky SH, Mills CA, Pearce KH, Herring LE, et al. I. PROTAC linkerology leads to an optimized bivalent chemical degrader of polycomb repressive complex 2 (PRC2) components. ACS Chem Biol. 2022;18(3):494–507.
   Web of Science ®Google Scholar
• Park KS, Qin L, Kabir M, Luo K, Dale B, Zhong Y, Kim A, Wang GG, Kaniskan HÜ, Jin J. Targeted degradation of PRC1 components, BMI1 and RING1B, via a novel protein complex degrader strategy. Adv Sci. 2023;10(10):e2205573.
   Web of Science ®Google Scholar
• Xu C, Meng F, Park KS, Storey AJ, Gong W, Tsai YH, Gibson E, Byrum SD, Li D, Edmondson RD, et al. A NSD3-targeted PROTAC suppresses NSD3 and CMyc oncogenic nodes in cancer cells. Cell Chem Biol. 2022;29(3):386.e9–397.e9.
   Web of Science ®Google Scholar
• Sun Y, Zhang Y, Chen X, Yu A, Du W, Huang Y, Wu F, Yu L, Li J, Wen C, et al. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase. Eur J Med Chem. 2022;239:114528.
   PubMed Web of Science ®Google Scholar
• Meng F, Xu C, Park KS, Kaniskan HÜ, Wang GG, Jin J. Discovery of a first-in-class degrader for nuclear receptor binding SET domain protein 2 (NSD2) and Ikaros/Aiolos. J Med Chem. 2022;65(15):10611–10625.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wu W, Jia K, Qi G, Sun XS, Li P. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1. Eur J Med Chem. 2022;244:114830.
   PubMed Web of Science ®Google Scholar
• Yu X, Wang J, Gong W, Ma A, Shen Y, Zhang C, Liu X, Cai L, Liu J, Wang GG, et al. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene. 2023;42(13):994–1009.
   PubMed Web of Science ®Google Scholar
• Wang J, Park KS, Yu X, Gong W, Earp HS, Wang GG, Jin J, Cai L. A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation. Nucleic Acids Res. 2022;50(19):10929–10946.
   PubMed Web of Science ®Google Scholar
• Lüscher B, Ahel I, Altmeyer M, Ashworth A, Bai P, Chang P, Cohen M, Corda D, Dantzer F, Daugherty MD, et al. ADP-ribosyltransferases, an update on function and nomenclature. FEBS J. 2022; 289 (23):7399–7410.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH. An update on Poly(ADP-Ribose)Polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J Med Chem. 2016;59(21):9575–9598.
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl] -2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-Ribose) polymerase-1. J Med Chem. 2008; 51 (20):6581–6591.
   PubMed Web of Science ®Google Scholar
• Jones P, Wilcoxen K, Rowley M, Toniatti C. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem. 2015;58(8):3302–3314.
   PubMed Web of Science ®Google Scholar
• Sun Y, Ding H, Liu X, Li X, Li L. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells. Tumour Biol. 2014;35(5):4469–4477.
   PubMedGoogle Scholar
• Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003–5015.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
   PubMed Web of Science ®Google Scholar
• Peng X, Pan W, Jiang F, Chen W, Qi Z, Peng W, Chen J. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. Pharmacol Res. 2022;186:106529.
   PubMed Web of Science ®Google Scholar
• Wang S, Han L, Han J, Li P, Ding Q, Zhang QJ, Liu ZP, Chen C, Yu Y. Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. Nat Chem Biol. 2019;15(12):1223–1231.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chang X, Zhang C, Zeng S, Liang M, Ma Z, Wang Z, Huang W, Shen Z. Identification of probe-quality degraders for poly(ADP-Ribose) polymerase-1 (PARP-1). J Enzyme Inhib Med Chem. 2020;35(1):1606–1615.
   PubMed Web of Science ®Google Scholar
• Cao C, Yang J, Chen Y, Zhou P, Wang Y, Du W, Zhao L, Chen Y. Discovery of SK-575 as a highly potent and efficacious proteolysis-targeting chimera degrader of PARP1 for treating cancers. J Med Chem. 2020;63(19):11012–11033.
   PubMed Web of Science ®Google Scholar
• Lin S, Tu G, Yu Z, Jiang Q, Zhang L, Liu J, Liu Q, Huang X, Xu J, Lin Y, et al. Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the CGAS/STING immunity pathway combined with daunorubicin. Bioorg Med Chem. 2022;70:116912.
   PubMed Web of Science ®Google Scholar
• Li G, Lin S. s, Yu Z. l, Wu X. h, Liu J. w, Tu G. h, Liu Q. y, Tang Y. l, Jiang Q. n, Xu J. h, et al. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in P53-positive breast cancer. Biochem Pharmacol. 2022; 206:115329.
   PubMed Web of Science ®Google Scholar
• Pu C, Wang S, Luo D, Liu Y, Ma X, Zhang H, Yu S, Lan S, Huang Q, Deng R, et al. Synthesis and biological evaluation of a tumor-selective degrader of PARP1. Bioorg Med Chem. 2022;69:116908.
   PubMed Web of Science ®Google Scholar
• Wigle TJ, Ren Y, Molina JR, Blackwell DJ, Schenkel LB, Swinger KK, Kuplast-Barr K, Majer CR, Church WD, Lu AZ, et al. Targeted degradation of PARP14 using a heterobifunctional small molecule. Chembiochem. 2021;22(12):2107–2110.
   PubMed Web of Science ®Google Scholar
• Zheng M, Huo J, Gu X, Wang Y, Wu C, Zhang Q, Wang W, Liu Y, Liu Y, Zhou X, et al. Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP. J Med Chem. 2021;64(11):7839–7852.
   PubMed Web of Science ®Google Scholar
• Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, et al. Selective Degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer. Eur J Med Chem. 2022;236:114321.
   PubMed Web of Science ®Google Scholar
• Duan S, Pagano M. Ubiquitin ligases in cancer: functions and clinical potentials. Cell Chem Biol. 2021;28(7):918–933.
   PubMed Web of Science ®Google Scholar
• Steinebach C, Lindner S, Udeshi ND, Mani DC, Kehm H, Köpff S, Carr SA, Gütschow M, Krönke J. Homo-PROTACs for the chemical knockdown of cereblon. ACS Chem Biol. 2018;13(9):2771–2782.
   PubMed Web of Science ®Google Scholar
• He S, Ma J, Fang Y, Liu Y, Wu S, Dong G, Wang W, Sheng C. Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer. Acta Pharm Sin B. 2021;11(6):1617–1628.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, Yang CY, Wang M, Han X, Wang S. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J Med Chem. 2019;62(2):448–466.
   PubMed Web of Science ®Google Scholar
• Qi Z, Yang G, Deng T, Wang J, Zhou H, Popov SA, Shults EE, Wang C. Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein. Bioorg Chem. 2021;111:104901.
   PubMed Web of Science ®Google Scholar
• Marcellino BK, Yang X, Ümit Kaniskan H, Brady C, Chen H, Chen K, Qiu X, Clementelli C, Herschbein L, Li Z, et al. An MDM2 degrader for treatment of acute leukemias. Leukemia. 2023;37(2):370–378.
   PubMed Web of Science ®Google Scholar
• Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands article. Nat Chem Biol. 2018;14(4):405–412.
   PubMed Web of Science ®Google Scholar
• Park S, Kim D, Lee W, Cho JH, Kim S, Lee GS, Moon JH, Kim JA, Ha JD, Kim JH, et al. Discovery of Pan-IAP degraders via a CRBN recruiting mechanism. Eur J Med Chem. 2023;245(Pt 2):114910.
   PubMedGoogle Scholar
• Chen H, Nguyen NH, Magtoto CM, Cobbold SA, Bidgood GM, Meza Guzman LG, Richardson LW, Corbin J, Au AE, Lechtenberg BC, et al. Design and characterization of a heterobifunctional degrader of KEAP1. Redox Biol. 2023;59:102552.
   PubMed Web of Science ®Google Scholar
• Wang B, Wu S, Liu J, Yang K, Xie H, Tang W. Development of selective small molecule MDM2 degraders based on nutlin. Eur J Med Chem. 2019;176:476–491.
   PubMed Web of Science ®Google Scholar
• Adams CM, Mitra R, Xiao Y, Michener P, Palazzo J, Chao A, Gour J, Cassel J, Salvino JM, Eischen CM. Targeted MDM2 degradation reveals a new vulnerability for P53 inactivated triple negative breast cancer. Cancer Discov. 2023;13(5):1210–1229.
   PubMed Web of Science ®Google Scholar
• Girardini M, Maniaci C, Hughes SJ, Testa A, Ciulli A. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. Bioorg Med Chem. 2019;27(12):2466–2479.
   PubMed Web of Science ®Google Scholar
• Steinebach C, Kehm H, Lindner S, Vu LP, Köpff S, López Mármol Á, Weiler C, Wagner KG, Reichenzeller M, Krönke J, et al. PROTAC-mediated crosstalk between E3 ligases. Chem Commun. 2019; 55 (12):1821–1824.
   PubMed Web of Science ®Google Scholar
• Kim K, Lee DH, Park S, Jo SH, Ku B, Park SG, Park BC, Jeon YU, Ahn S, Kang CH, et al. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. Sci Rep. 2019;9(1):19654.
   PubMedGoogle Scholar
• Powell CE, Du G, Bushman JW, He Z, Zhang T, Fischer ES, Gray NS. Selective degradation-inducing probes for studying cereblon (CRBN) biology. RSC Med Chem. 2021;12(8):1381–1390.
   PubMedGoogle Scholar
• Ng YLD, Bricelj A, Jansen JA, Murgai A, Peter K, Donovan KA, Gütschow M, Krönke J, Steinebach C, Sosič I. Heterobifunctional ligase recruiters enable pan-degradation of inhibitor of apoptosis proteins. J Med Chem. 2023;66 (7):4703–4733.
   PubMed Web of Science ®Google Scholar
• Du G, Jiang J, Henning NJ, Safaee N, Koide E, Nowak RP, Donovan KA, Yoon H, You I, Yue H, et al. Exploring the target scope of KEAP1 E3 ligase-based PROTACs. Cell Chem Biol. 2022;29(10):1470.e31–1481.e31.
   Web of Science ®Google Scholar
• Kussie PH, Gorina S, Marechal V, Elenbaas B.  Structure of the MDM2 oncoprotein bound to the P53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948–953.
   PubMed Web of Science ®Google Scholar
• Yang J, Li Y, Aguilar A, Liu Z, Yang CY, Wang S. Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders. J Med Chem. 2019;62(21):9471–9487.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu J, Tandon I, Wu S, Teng P, Liao J, Tang W. Development of MDM2 degraders based on ligands derived from ugi reactions: lessons and discoveries. Eur J Med Chem. 2021;219:113425.
   PubMed Web of Science ®Google Scholar
• Ishoey M, Chorn S, Singh N, Jaeger MG, Brand M, Paulk J, Bauer S, Erb MA, Parapatics K, Müller AC, et al. Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem Biol. 2018;13(3):553–560.
   PubMed Web of Science ®Google Scholar
• Allton K, Jain AK, Herz H-M, Tsai W-W, Jung SY, Qin J, Bergmann A, Johnson RL, Barton MC. Trim24 targets endogenous P53 for degradation. Proc Natl Acad Sci U S A. 2009;106(28):11612–11616.
   PubMed Web of Science ®Google Scholar
• Takaya K, Suzuki T, Motohashi H, Onodera K, Satomi S, Kensler TW, Yamamoto M. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med. 2012;53(4):817–827.
   PubMed Web of Science ®Google Scholar
• Zong Z, Zhang Z, Wu L, Zhang L, Zhou F. The functional deubiquitinating enzymes in control of innate antiviral immunity. Adv Sci. 2021;8(2):2002484.
   Web of Science ®Google Scholar
• Wang Y, Wang F. Post-translational modifications of deubiquitinating enzymes: expanding the ubiquitin code. Front Pharmacol. 2021;12:685011.
   PubMed Web of Science ®Google Scholar
• Pei Y, Fu J, Shi Y, Zhang M, Luo G, Luo X, Song N, Mi T, Yang Y, Li J, et al. Discovery of a potent and selective degrader for USP7. Angew Chem Int Ed Engl. 2022;61(33):e202204395.
   PubMed Web of Science ®Google Scholar
• Murgai A, Sosič I, Gobec M, Lemnitzer P, Proj M, Wittenburg S, Voget R, Gütschow M, Krönke J, Steinebach C. Targeting the deubiquitinase USP7 for degradation with PROTACs. Chem Commun. 2022;58(63):8858–8861.
   PubMed Web of Science ®Google Scholar
• Simpson LM, Glennie L, Brewer A, Zhao J-F, Crooks J, Shpiro N, Sapkota GP. Target protein localization and its impact on PROTAC-mediated degradation. Cell Chem Biol. 2022;29(10):1482.e7–1504.e7.
   Web of Science ®Google Scholar
• Zhang X, Thummuri D, He Y, Liu X, Zhang P, Zhou D, Zheng G. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem Commun. 2019;55(98):14765–14768.
   PubMed Web of Science ®Google Scholar
• Jevtić P, Haakonsen DL, Rapé M. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. Cell Chem Biol. 2021;28(7):1000–1013.
   PubMed Web of Science ®Google Scholar